
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

500 experts at the 7th AMR Conference in Basel
That antimicrobial resistance can no longer be considered a silent pandemic became abundantly clear at the AMR Conference in Basel from March 16-17....

Iktos SA raises €15.5m in Series A financing
aThe Series A financing of Iktos was co-led by new investors M Ventures and Debiopharm Innovation Fund with participation...

High blood pressure reprograms immune system
German scientists headed by Suphansa Sawamiphak from MDC Berlin have discovered in a zebrafish and mouse model of salt-induced hypertension that...

Pfizer-Seagen: Acquisition in the works
As announced earlier this week, Pfizer Inc. plans to purchase Seagen for US$43bn. The Boards of Directors of both companies approved the transaction...

Roche’s meets endpoints in relapsing multiple sclerosis
In patients with relapsing-remitting multiple sclerosis (RRMS), fenebrutinib significantly reduced the total number of new gadolinium-enhancing...